Biomarkers for prostate cancer detection (Q37656233)

21 August 2017

1 reference

title

Biomarkers for prostate cancer detection (English)

1 reference

21 August 2017

0 references

1 reference

Amanda Beth Reed

1

1 reference

PubMed ID

20014890

21 August 2017

Dipen J Parekh

series ordinal

2

1 reference

21 August 2017

1 January 2010

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

103-114

1 reference

21 August 2017

1

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Phases of biomarker development for early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Autoantibodies to prostasomes as new markers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Proteomic applications for the early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Serum proteomic patterns for detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Emerging biomarkers for the diagnosis and prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Early identification of individuals with prostate cancer in negative biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

EPCA-2: a highly specific serum marker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Fusion in the ETS gene family and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prostate stem cell antigen: a prospective therapeutic and diagnostic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Role of prostate stem cell antigen in prostate cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Methylation-specific PCR for detection of neoplastic DNA in biopsy washings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

DNA-based detection of prostate cancer in urine after prostatic massage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Delineation of prognostic biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Circulating biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Sample size planning for developing classifiers using high-dimensional DNA microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Assessment of diagnostic tests when disease verification is subject to selection bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Assessment of 54 biomarkers for biopsy-detectable prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Autoantibody signatures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Signal in Noise: Evaluating Reported Reproducibility of Serum Proteomic Tests for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.168

21 January 2018

Identifiers

DOI

10.1586/ERA.09.168

1 reference

21 August 2017

1 reference

PubMed ID

20014890